Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hollander, P. A.
Right arrow Articles by Hauptman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollander, P. A.
Right arrow Articles by Hauptman, J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 8 1288-1294, Copyright © 1998 by American Diabetes Association

ARTICLES

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

PA Hollander, SC Elbein, IB Hirsch, D Kelley, J McGill, T Taylor, SR Weiss, SE Crockett, RA Kaplan, J Comstock, CP Lucas, PA Lodewick, W Canovatchel, J Chung and J Hauptman
Baylor Medical Center, Dallas, Texas, USA.

OBJECTIVE: Obesity is an important risk factor for type 2 diabetes. Weight loss in patients with type 2 diabetes is associated with improved glycemic control and reduced cardiovascular disease risk factors, but weight loss is notably difficult to achieve and sustain with caloric restriction and exercise. The purpose of this study was to assess the impact of treatment with orlistat, a pancreatic lipase inhibitor, on weight loss, glycemic control, and serum lipid levels in obese patients with type 2 diabetes on sulfonylurea medications. RESEARCH DESIGN AND METHODS: In a multicenter 57-week randomized double-blind placebo-controlled study, 120 mg orlistat or placebo was administered orally three times a day with a mildly hypocaloric diet to 391 obese men and women with type 2 diabetes who were aged > 18 years, had a BMI of 28-40 kg/m2, and were clinically stable on oral sulfonylureas. Changes in body weight, glycemic control, lipid levels, and drug tolerability were measured. RESULTS: After 1 year of treatment, the orlistat group lost 6.2 +/- 0.45% (mean +/- SEM) of initial body weight vs. 4.3 +/- 0.49% in the placebo group (P < 0.001). Twice as many patients receiving orlistat (49 vs. 23%) lost > or = 5% of initial body weight (P < 0.001). Orlistat treatment plus diet compared with placebo plus diet was associated with significant improvement in glycemic control, as reflected in decreases in HbA1c (P < 0.001) and fasting plasma glucose (P < 0.001) and in dosage reductions of oral sulfonylurea medication (P < 0.01). Orlistat therapy also resulted in significantly greater improvements than placebo in several lipid parameters, namely, greater reductions in total cholesterol, (P < 0.001), LDL cholesterol (P < 0.001), triglycerides (P < 0.05), apolipoprotein B (P < 0.001), and the LDL-to-HDL cholesterol ratio (P < 0.001). Mild to moderate and transient gastrointestinal events were reported with orlistat therapy, although their association with study withdrawal was low. Fat-soluble vitamin levels generally remained within the reference range, and vitamin supplementation was required in only a few patients. CONCLUSIONS: Orlistat is an effective treatment modality in obese patients with type 2 diabetes with respect to clinically meaningful weight loss and maintenance of weight loss, improved glycemic control, and improved lipid profile.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Ellrichmann, M. Kapelle, P. R. Ritter, J. J. Holst, K.-H. Herzig, W. E. Schmidt, F. Schmitz, and J. J. Meier
Orlistat Inhibition of Intestinal Lipase Acutely Increases Appetite and Attenuates Postprandial Glucagon-Like Peptide-1-(7-36)-Amide-1, Cholecystokinin, and Peptide YY Concentrations
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3995 - 3998.
[Abstract] [Full Text] [PDF]

Home page
 Menopause IntHome page
A. Samat, A. Rahim, and A. Barnett
Pharmacotherapy for obesity in menopausal women
Menopause Int, June 1, 2008; 14(2): 57 - 62.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. T. Boyd
Management Through Risk Factor Modification
The Diabetes Educator, March 1, 2008; 34(Supplement_2): 42S - 48S.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
P. Hollander
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Diabetes Spectr, July 1, 2007; 20(3): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. A. Bray and F. L. Greenway
Pharmacological Treatment of the Overweight Patient
Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184.
[Full Text] [PDF]

Home page
 CMAJHome page
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and for members of the Obesity Canada Clinical Practic
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
Can. Med. Assoc. J., April 10, 2007; 176(8): S1 - S13.
[Full Text] [PDF]

Home page
 CMAJHome page
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and pour les membres du Groupe d'experts d'Obesite Can
Lignes directrices canadiennes de 2006 sur la prise en charge et la prevention de l'obesite chez les adultes et les enfants [sommaire]
Can. Med. Assoc. J., April 10, 2007; 176(8): SF1 - SF14.
[Full Text] [PDF]

Home page
 CirculationHome page
K. M. Gadde and D. B. Allison
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Circulation, August 29, 2006; 114(9): 974 - 984.
[Full Text] [PDF]

Home page
 JAMAHome page
J.-P. Chanoine, S. Hampl, C. Jensen, M. Boldrin, and J. Hauptman
Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial
JAMA, June 15, 2005; 293(23): 2873 - 2883.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Redmon, K. P. Reck, S. K. Raatz, J. E. Swanson, C. A. Kwong, H. Ji, W. Thomas, and J. P. Bantle
Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes
Diabetes Care, June 1, 2005; 28(6): 1311 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
Z. Li, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L. R. Shugarman, L. Hilton, M. Suttorp, V. Solomon, P. G. Shekelle, et al.
Meta-Analysis: Pharmacologic Treatment of Obesity
Ann Intern Med, April 5, 2005; 142(7): 532 - 546.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Y.Y. Cheng and I. G. Fantus
Oral antihyperglycemic therapy for type 2 diabetes mellitus
Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
B. Hutton and D. Fergusson
Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials
Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1461 - 1468.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Klein, L. E. Burke, G. A. Bray, S. Blair, D. B. Allison, X. Pi-Sunyer, Y. Hong, and R. H. Eckel
Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Circulation, November 2, 2004; 110(18): 2952 - 2967.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Damci, S. Yalin, H. Balci, Z. Osar, U. Korugan, M. Ozyazar, and H. Ilkova
Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz et al.
Diabetes Care, November 1, 2004; 27(11): 2771 - 2771.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. L. Norris, X. Zhang, A. Avenell, E. Gregg, C. H. Schmid, C. Kim, and J. Lau
Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus: A Meta-analysis
Arch Intern Med, July 12, 2004; 164(13): 1395 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. Wilding
Obesity treatment: the key to managing the type 2 diabetes timebomb?
The British Journal of Diabetes & Vascular Disease, July 1, 2004; 4(4): 217 - 219.
[PDF]

Home page
 Diabetes CareHome page
A. M. Wolf, M. R. Conaway, J. Q. Crowther, K. Y. Hazen, J. L.Nadler, B. Oneida, and V. E. Bovbjerg
Translating Lifestyle Intervention to Practice in Obese Patients With Type 2 Diabetes: Improving Control with Activity and Nutrition (ICAN) study
Diabetes Care, July 1, 2004; 27(7): 1570 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Damci, S. Yalin, H. Balci, Z. Osar, U. Korugan, M. Ozyazar, and H. Ilkova
Orlistat Augments Postprandial Increases in Glucagon-like Peptide 1 in Obese Type 2 Diabetic Patients
Diabetes Care, May 1, 2004; 27(5): 1077 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. E. Kelley, L. H. Kuller, T. M. McKolanis, P. Harper, J. Mancino, and S. Kalhan
Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 33 - 40.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. M. McTigue, R. Harris, B. Hemphill, L. Lux, S. Sutton, A. J. Bunton, and K. N. Lohr
Screening and Interventions for Obesity in Adults: Summary of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, December 2, 2003; 139(11): 933 - 949.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. W. F. Wilson and S. M. Grundy
The Metabolic Syndrome: Practical Guide to Origins and Treatment: Part I
Circulation, September 23, 2003; 108(12): 1422 - 1424.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Redmon, S. K. Raatz, K. P. Reck, J. E. Swanson, C. A. Kwong, Q. Fan, W. Thomas, and J. P. Bantle
One-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes: A randomized trial
Diabetes Care, September 1, 2003; 26(9): 2505 - 2511.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Pilichiewicz, D. O'Donovan, C. Feinle, Y. Lei, J. M. Wishart, L. Bryant, J. H. Meyer, M. Horowitz, and K. L. Jones
Effect of Lipase Inhibition on Gastric Emptying of, and the Glycemic and Incretin Responses to, an Oil/Aqueous Drink in Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3829 - 3834.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. I. Berkowitz, T. A. Wadden, A. M. Tershakovec, and J. L. Cronquist
Behavior Therapy and Sibutramine for the Treatment of Adolescent Obesity: A Randomized Controlled Trial
JAMA, April 9, 2003; 289(14): 1805 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
P. A. Hollander, P. Levy, M. S. Fineman, D. G. Maggs, L. Z. Shen, S. A. Strobel, C. Weyer, and O. G. Kolterman
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial
Diabetes Care, March 1, 2003; 26(3): 784 - 790.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
S. J Parikh and J. A Yanovski
Calcium intake and adiposity
Am. J. Clinical Nutrition, February 1, 2003; 77(2): 281 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. D. Mooradian
Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines
Arch Intern Med, January 13, 2003; 163(1): 33 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. J. McNulty, E. Ur, and G. Williams
A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin
Diabetes Care, January 1, 2003; 26(1): 125 - 131.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M Labib
The investigation and management of obesity
J. Clin. Pathol., January 1, 2003; 56(1): 17 - 25.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
A. Astrup
Is there any conclusive evidence that exercise alone reduces glucose intolerance?
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S18 - S23.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
P. C. Y. Tong, Z. S. K. Lee, M.-M. Sea, C.-C. Chow, G. T. C. Ko, W.-B. Chan, W.-Y. So, R. C. W. Ma, R. Ozaki, J. Woo, et al.
The Effect of Orlistat-Induced Weight Loss, Without Concomitant Hypocaloric Diet, on Cardiovascular Risk Factors and Insulin Sensitivity in Young Obese Chinese Subjects With or Without Type 2 Diabetes
Arch Intern Med, November 25, 2002; 162(21): 2428 - 2435.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
K. Narbro, G. Agren, E. Jonsson, I. Naslund, L. Sjostrom, and M. Peltonen
Pharmaceutical Costs in Obese Individuals: Comparison With a Randomly Selected Population Sample and Long-term Changes After Conventional and Surgical Treatment: The SOS Intervention Study
Arch Intern Med, October 14, 2002; 162(18): 2061 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
S. E. Greenway, F. L. Greenway III, and S. Klein
Effects of Obesity Surgery on Non-Insulin-Dependent Diabetes Mellitus
Arch Surg, October 1, 2002; 137(10): 1109 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Edelsberg, D. Weycker, and G. Oster
Response to Lamotte et al.
Diabetes Care, October 1, 2002; 25(10): 1899 - 1900.
[Full Text]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
American Association of Clinical Endocrinologists Meeting, May 2002
Diabetes Care, August 1, 2002; 25(8): 1464 - 1471.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Miles, L. Leiter, P. Hollander, T. Wadden, J. W. Anderson, M. Doyle, J. Foreyt, L. Aronne, and S. Klein
Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin
Diabetes Care, July 1, 2002; 25(7): 1123 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. E. Kelley, G. A. Bray, F. X. Pi-Sunyer, S. Klein, J. Hill, J. Miles, and P. Hollander
Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes: A 1-year randomized controlled trial
Diabetes Care, June 1, 2002; 25(6): 1033 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Z. Yanovski and J. A. Yanovski
Obesity
N. Engl. J. Med., February 21, 2002; 346(8): 591 - 602.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Lamotte, L. Annemans, A. Lefever, M. Nechelput, and J. Masure
A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients
Diabetes Care, February 1, 2002; 25(2): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, et al.
Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications
Diabetes Care, January 1, 2002; 25(1): 148 - 198.
[Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. Pinkney
Review: Implications of obesity for diabetes and coronary heart disease in clinical practice
The British Journal of Diabetes & Vascular Disease, November 1, 2001; 1(2): 103 - 106.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
G. Glazer
Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety
Arch Intern Med, August 13, 2001; 161(15): 1814 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
D. Arterburn and P. H. Noel
Extracts from ""Clinical Evidence"": Obesity
BMJ, June 9, 2001; 322(7299): 1406 - 1409.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
American Diabetes Association 60th Scientific Sessions, 2000: Cardiovascular disease in diabetes
Diabetes Care, February 1, 2001; 24(2): 399 - 404.
[Full Text]

Home page
 Arch Intern MedHome page
T. A. Wadden, R. I. Berkowitz, D. B. Sarwer, R. Prus-Wisniewski, and C. Steinberg
Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity: A Randomized Trial
Arch Intern Med, January 22, 2001; 161(2): 218 - 227.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. J. Hukshorn, W. H. M. Saris, M. S. Westerterp-Plantenga, A. R. Farid, F. J. Smith, and L. A. Campfield
Weekly Subcutaneous Pegylated Recombinant Native Human Leptin (PEG-OB) Administration in Obese Men
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4003 - 4009.
[Abstract] [Full Text]

Home page
 Am. J. Clin. Nutr.Home page
J. W Anderson and E. C Konz
Benefits and risks of antiobesity agents
Am. J. Clinical Nutrition, March 1, 2000; 71 (3): 844 - 845.
[Full Text] [PDF]

Home page
 Arch Fam MedHome page
J. Hauptman, C. Lucas, M. N. Boldrin, H. Collins, and K. R. Segal
Orlistat in the Long-term Treatment of Obesity in Primary Care Settings
Arch Fam Med, February 1, 2000; 9(2): 160 - 167.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. A. Bray and F. L. Greenway
Current and Potential Drugs for Treatment of Obesity
Endocr. Rev., December 1, 1999; 20(6): 805 - 875.
[Abstract] [Full Text]

Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
J.M. Tremble and D. Donaldson
Is continued weight gain inevitable in type 2 diabetes mellitus?
Perspectives in Public Health, December 1, 1999; 119(4): 235 - 239.
[Abstract] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
S. Klein
The war against obesity: attacking a new front
Am. J. Clinical Nutrition, June 1, 1999; 69(6): 1061 - 1063.
[Full Text] [PDF]

Home page
 JAMAHome page
D. F. Williamson
Pharmacotherapy for Obesity
JAMA, January 20, 1999; 281(3): 278 - 280.
[Full Text] [PDF]

Home page
 DTBHome page
Why and how should adults lose weight?
DTB, December 1, 1998; 36(12): 89 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Journal Watch DermatologyHome page
Orlistat, a New Drug for Weight Reduction
Journal Watch Dermatology, October 1, 1998; 1998(1001): 19 - 19.
[Full Text]

Home page
 JWatch GeneralHome page
Orlistat, a New Drug for Weight Reduction
Journal Watch (General), August 21, 1998; 1998(821): 1 - 1.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care